SAM
Simplify Asset Management Portfolio holdings
AUM
$1.65B
1-Year Return
8.73%
This Quarter Return
+7%
1 Year Return
+8.73%
3 Year Return
+37.73%
5 Year Return
–
10 Year Return
–
AUM
$1.04B
AUM Growth
+$398M
(+62%)
Cap. Flow
+$345M
Cap. Flow
% of AUM
33.1%
Top 10 Holdings %
Top 10 Hldgs %
81.33%
Holding
138
New
25
Increased
32
Reduced
16
Closed
30
Top Buys
| 1 |
iShares Core S&P 500 ETF
IVV
|
$202M |
| 2 |
Simplify Stable Income ETF
BUCK
|
$52.9M |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
$50M |
| 4 |
Intuitive Surgical
ISRG
|
$10.7M |
| 5 |
Sarepta Therapeutics
SRPT
|
$8.65M |
Top Sells
| 1 |
PIMCO 15+ Year US TIPS Index Exchange-Traded Fund
LTPZ
|
$11.2M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
$9.8M |
| 3 |
iShares MBS ETF
MBB
|
$5.38M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$4.09M |
| 5 |
Masimo
MASI
|
$3.98M |
Sector Composition
| 1 | Healthcare | 18.76% |
| 2 | Energy | 2.4% |
| 3 | Industrials | 0.84% |
| 4 | Technology | 0.49% |
| 5 | Real Estate | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
iShares Gold Trust
IAU
$52B
| $1.81M | 0.11% |
43,200
-5,514
| -11% | -$232K |
|
52
Syndax Pharmaceuticals
SNDX
$1.39B
| $1.79M | 0.11% |
75,337
+63,536
| +538% | +$1.51M |
|
53
AGNC Investment
AGNC
$10.6B
| $1.78M | 0.11% |
180,000
| – | – |
|
54
Mirum Pharmaceuticals
MIRM
$3.73B
| $1.76M | 0.1% |
70,000
| – | – |
|
55
Kura Oncology
KURA
$706M
| $1.71M | 0.1% |
80,000
| – | – |
|
56
Idexx Laboratories
IDXX
$51.2B
| $1.52M | 0.09% |
2,819
+1,504
| +114% | +$812K |
|
57
Kayne Anderson Energy Infrastructure Fund
KYN
$2.08B
| $1.47M | 0.09% |
147,033
| – | – |
|
|
58
Masimo
MASI
$7.77B
| $1.44M | 0.09% |
9,832
-27,084
| -73% | -$3.98M |
|
59
Ultragenyx Pharmaceutical
RARE
$3.01B
| $1.44M | 0.09% |
+30,753
| New | +$1.44M |
|
|
MRNS
60
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.36M | 0.08% |
150,000
| – | – |
|
61
Establishment Labs
ESTA
$1.12B
| $1.3M | 0.08% |
25,493
+13,630
| +115% | +$694K |
|
62
Kymera Therapeutics
KYMR
$3.02B
| $1.23M | 0.07% |
30,515
| – | – |
|
63
Natera
NTRA
$22.9B
| $1.16M | 0.07% |
+12,669
| New | +$1.16M |
|
64
Leap Therapeutics
LPTX
$11.7M
| $1M | 0.06% |
+375,976
| New | +$1M |
|
65
Achieve Life Sciences
ACHV
$143M
| $990K | 0.06% |
+217,845
| New | +$990K |
|
66
Abbott
ABT
$231B
| $962K | 0.06% |
8,467
+4,512
| +114% | +$513K |
|
67
UnitedHealth
UNH
$281B
| $940K | 0.06% |
1,900
-1,611
| -46% | -$797K |
|
68
NVIDIA
NVDA
$4.18T
| $932K | 0.06% |
10,320
| – | – |
|
69
Advanced Micro Devices
AMD
$263B
| $791K | 0.05% |
4,383
| – | – |
|
70
Lumen
LUMN
$5.1B
| $780K | 0.05% |
+500,000
| New | +$780K |
|
|
EMD
71
Western Asset Emerging Markets Debt Fund
EMD
$598M
| $769K | 0.05% |
+80,000
| New | +$769K |
|
72
Trevi Therapeutics
TRVI
$880M
| $690K | 0.04% |
+200,000
| New | +$690K |
|
73
Sutro Biopharma
STRO
$86.5M
| $678K | 0.04% |
120,000
| – | – |
|
|
OXLC
74
Oxford Lane Capital
OXLC
$1.77B
| $646K | 0.04% |
+127,068
| New | +$646K |
|
75
Bio-Techne
TECH
$8.23B
| $644K | 0.04% |
9,152
+4,888
| +115% | +$344K |
|